Comvita Limited Stocks

NZ$ 0.67Last Updated 29.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

NZ$ 28.60M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NZ$ 0.67
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Comvita Limited, together with its subsidiaries, engages in manufacturing and marketing natural health products in Australia, New Zealand, China, rest of Asia, North America, Europe, the Middle East, Africa, and internationally. The company offers Manuka honey, propolis, olive leaf extract, medihoney and skincare, gourmet honey, elixirs and lozenges, and cider vinegar products, as well as oral and kids health products. It also provides solutions for digestive health, eczema prone skin, energy, heart health, and immune support, as well as for summer and travel essentials. In addition, the company engages in the apiary ownership and management, property ownership, and IP ownership. Comvita Limited was incorporated in 1974 and is based in Te Puke, New Zealand.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, underpriced o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of CVT.NZ is 0.80 and suggests 19% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks